Regulus Therapeutics Inc (NASDAQ:RGLS) has earned an average rating of “Hold” from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $1.75.
RGLS has been the topic of several analyst reports. B. Riley initiated coverage on Regulus Therapeutics in a research report on Wednesday, March 28th. They set a “neutral” rating and a $1.00 price target on the stock. BMO Capital Markets set a $1.00 price target on Regulus Therapeutics and gave the stock a “hold” rating in a research report on Thursday, March 8th. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research report on Wednesday, May 16th. Wedbush reaffirmed an “outperform” rating and set a $3.00 price target on shares of Regulus Therapeutics in a research report on Thursday, May 17th. Finally, ValuEngine raised Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd.
Several hedge funds have recently bought and sold shares of RGLS. BVF Inc. IL boosted its stake in shares of Regulus Therapeutics by 7.9% during the 4th quarter. BVF Inc. IL now owns 13,974,249 shares of the biopharmaceutical company’s stock worth $14,533,000 after acquiring an additional 1,025,020 shares in the last quarter. Ascend Capital LLC purchased a new stake in shares of Regulus Therapeutics during the 4th quarter worth about $1,053,000. A.R.T. Advisors LLC purchased a new stake in shares of Regulus Therapeutics during the 1st quarter worth about $121,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Regulus Therapeutics by 215.7% during the 4th quarter. Renaissance Technologies LLC now owns 137,589 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 94,000 shares in the last quarter. 50.93% of the stock is currently owned by institutional investors and hedge funds.
Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative return on equity of 214.48% and a negative net margin of 94,318.05%. research analysts predict that Regulus Therapeutics will post -0.63 earnings per share for the current year.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.